Genetic assays have transformed how clinicians approach treatment decisions in breast cancer, offering both predictive and prognostic insight that helps tailor therapy to individu ...

A Decision Score provides prognostic discrimination for 10-year locoregional recurrence, with rising score associated with ...

RECKGIST score effectively predicts recurrence in neurofibromatosis type 1-associated GISTs, especially for tumors under 30 mm. Larger GISTs (over 30 mm) have a higher risk of metastasis, with ...

Women with early-stage hormone receptor (HR)-positive breast cancer who had low to intermediate scores on the Oncotype DX Breast Recurrence Score assay did just as well on neoadjuvant endocrine ...

Please provide your email address to receive an email when new articles are posted on . Further study is needed to identify potential drivers of the association Low household income appeared ...

The recurrence score based on the 21-gene breast-cancer assay has been clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human epidermal growth factor receptor 2 ...

MADISON, Wis., February 03, 2026--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its ...

Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non–Small Cell Lung Cancer RNA sequencing was performed on 647 previously untreated stage I-III estrogen receptor–positive/human ...

A risk score based on four factors — male sex, tumor size, World Health Organization (WHO) grade, and lymphovascular invasion — predicts recurrence in patients with node-negative pancreatic ...

"We have known that income level is associated with incidence of poor-prognosis triple-negative breast cancer, but our new study presents the first data to show that income level impacts survival even ...

Self-examination behavior varied markedly: roughly 20% reported none in the prior year, while about one-third examined weekly or monthly despite >90% rating checks as important. Nearly half of trial ...